Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Of Abuse-Deterrent Opioids Will Get FDA Guidance, Eventually

Executive Summary

FDA is developing a step-wise approach for developers of generic versions of opioids with an abuse-deterrence claim, but first it needs the results of two research projects.

You may also be interested in...



Final Generic Abuse-Deterrent Opioids Guidance Coming This Year

US FDA says it expects to finalize guidance by November, but more research is needed with generic development questions lingering.

Final Generic Abuse-Deterrent Opioids Guidance Coming This Year

US FDA says it expects to finalize guidance by November, but more research is needed with generic development questions lingering.

FDA In Twilight: Gov’t Shutdown Has Not Slowed Rx Operations Too Visibly Yet

Shutdown puts API shipments on a slow boat, but reviews of existing products can proceed with carry-over funds, even as new applications cannot be filed. CDC has largely halted its influenza program and NIH has ceased enrolling new patients in its clinical center.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel